Abstract: This disclosure provides to methods for treating Hodgkin lymphoma in a subject comprising nivolumab, a PD-1-blocking antibody, that inhibits tumor immune evasion in patients with relapsed or refractory Hodgkin's lymphoma.

Abstract: This invention relates to alpha-4 binding antibodies, and fragments thereof.

Abstract: The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.

Abstract: Compounds including a tetrapyrrolic or reduced tetrapyrrolic group/moiety and an epidermal growth factor receptor targeting group are disclosed. For example, a compound includes a tetrapyrrolic or reduced tetrapyrrolic group or moiety, a linker moiety, an epidermal growth factor receptor targeting group, and, optionally, a PET-active functional group. Uses of the compounds, for example, methods of treating a hyperproliferative tissue in an individual, and kits including one or more of the compounds are also provided.

Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.

Abstract: The invention provides an amorphous metal-organic framework for use in methods of treatment. The amorphous metal-organic framework may hold a component for delivery. The amorphous metal-organic framework is obtained or is obtainable by amorphization of a crystalline amorphous metal-organic framework holding the component. The amorphous metal-organic framework may be a zirconium-containing or a bismuth-containing metal-organic framework, such as a framework having arylcarboxylate ligands, such as benzenedicarboxylate ligands.

Abstract: The present invention is related to methods for lowering peroxide levels in sucrose acetate isobutyrate formulations and to composition used in and formed by such methods.

Abstract: Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent. Also disclosed are low viscosity delivery systems for administration of active agents. The low viscosity delivery systems have a polyorthoester polymer, a polar aprotic solvent and a solvent containing a triglyceride viscosity reducing agent. Compositions described include an amide- or anilide-type local anesthetic of the “caine” classification, and a non-steroidal anti-inflammatory drug (NSAID), along with related methods, e.g., for treatment of post-operative pain or for prophylactic treatment of pain. The compositions are suitable for delivery via, e.g., direct application and instillation, intradermal injection, subcutaneous injection, and nerve block (perineural).

Abstract: Disclosed are a conjugate including a mitochondria-targeting moiety and a peptide molecule capable of self-assembly; and a pharmaceutical composition for preventing or treating cancer including the conjugate as an active ingredient.

Abstract: Materials and methods for treating a patient with hereditary hemochromatosis (HHC), both ex vivo and in vivo, and materials and methods for modulating the expression, function, or activity of a haemochromatosis (HFE) gene in a cell by genome editing.

Abstract: Methods of making and using recombinant AAV virions with decreased immunoreactivity are described. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes and isolates that display decreased immunoreactivity relative to AAV-2.

Abstract: Methods of treating hemophilia A in a subject with an F8 gene mutation, wherein the F8 gene is repaired and the resultant repaired gene, upon expression, confers improved coagulation functionality to the encoded FVIII protein of the subject compared to the non-repaired F8 gene. The invention also includes methods of inducing immune tolerance to a FVIII replacement product ((r)FVIII) in a subject having a FVIII deficiency, wherein the F8 gene mutation is repaired and the repaired gene, upon expression, provides for the induction of immune tolerance to an administered replacement FVIII protein product. The invention also includes isolated nucleic acids, vectors, recombinant viruses, cells, and pharmaceutical compositions to repair the F8 gene.

Abstract: Implantable materials visible under ultrasound may delivered to a selected placement site and biodegrade after a certain period of time. Ultrasound visible implantable materials may be delivered through an applicator and may include ultrasound contrast agents and/or radiopaque agents. Applications include monitoring the delivery of an implant of the implantable materials to the placement site with ultrasound and delivery of therapeutic agents to a tissue at the placement site for treating a patient.

Abstract: A sterile aqueous composition suitable for use as an MRI contrast agent includes 100 to 600 mM ascorbate; and 100-600 mM sodium, meglumine, or a combination thereof. The composition preferably has an osmolarity of 200 to 1400 mOsm/L.

Abstract: It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [18F]FACBC, and which prevents methanol from remaining in the radioactive halogen-labeled amino acid compounds produced therefrom. The novel amino acid organic compound is a compound represented by the following formula: wherein n is an integer of 0 or of 1 to 4; R1 is an ethyl, 1-propyl or isopropyl substituent; X is a halogen substituent or a group represented by —OR2; R2 is a straight-chain or branched-chain haloalkylsulfonic acid substituent with one to 10 carbon atoms, trialkylstannyl substituent with 3 to 12 carbon atoms, fluorosulfonic acid substituent or aromatic sulfonic acid substituent; and R3 is a protective group.

Abstract: The present invention relates to probes for use in the detection, imaging, diagnosis, targeting, treatment, etc. of cancers expressing the gastrin releasing peptide receptor (GRPR). For example, such probes may be molecules conjugated to detectable labels which are preferably moieties suitable for detection by gamma imaging and SPECT or by positron emission tomography (PET) or magnetic resonance imaging (MRI) or fluorescence spectroscopy or optical imaging methods.

Abstract: Provided are radiopaque compositions comprising one or more of yttrium (Y), strontium (Sr), gallium (Ga), and silicon, or oxides and salts thereof. The composition can comprise a combination of Y2O3, SrO, Ga2O3, and SiO2, and optionally MnO2, and TiO2. Other compositions comprise SrO, Ga2O3, TiO2, MnO2, and SiO2. The composition can be a particulate material. The compositions are useful for radioembolization to treat tumors.

Abstract: A system for sterilizing viruses includes beam generation circuitry for generating a radiating wave having radiating energy therein at a predetermined frequency therein. A controller controls the radiating wave generation at the predetermined frequency. The predetermined frequency equals a resonance frequency of a particular virus. The predetermined frequency induces a mechanical resonance vibration at the resonance frequency of the particular virus within the particular virus for destroying a capsid of the particular virus. Radiating circuitry projects the radiating wave on a predetermined location to destroy the particular virus at the predetermined location.

Abstract: An improved pasteurisation protocol for pasteurising microbial cells is disclosed. The protocol has three stages, a first heating stage, a second plateau stage at which the cells are held at a (maximum and) constant temperature, and a third cooling stage. Both the heating and the cooling stages are rapid, with the temperature of the cells passing through 40 to 80° C. in no more than 30 minutes in the heating stage. The heating rate is at least 0.5° C./minute and during cooling is at least ?0.5° C./minute. The plateau maximum temperature is from 70 to 85° C. By plotting the pasteurisation protocol on a time (t, minutes) versus temperature (T, ° C.) graph, one obtains a trapezium having an area less than 13,000° C. minute. Not only does this result in a smaller energy input (and so a reduction in costs), but a better quality (and less oxidised) oil results having a peroxide value (POV) of less than 1.5 and an anisidine value (AnV) of less than 1.0.

Abstract: A sterilizer may include: a first pipe having an inner wall with a light reflecting property; a second pipe disposed in the first pipe so as to pass fluid therethrough and formed of a light transmitting material; and a plurality of UV LEDs arranged on the inner wall of the first pipe and configured to irradiate sterilization UV light onto the fluid.

Abstract: A control panel having a variety of potential applications that utilize ultraviolet-C (UV-C) light as a means of disinfection. In one embodiment, a human/machine interface (HMI) panel, such as a touchscreen or keypad uses a dynamically moveable multi-reflector assembly using UV-C light to disinfect its touch surfaces. The goal of integrating UV-C disinfection with an HMI works to provide a safe and effective dose of UV-C light to the panel's surface for the purpose of reducing the number of active pathogens.

Abstract: Various implementations of the invention are directed toward a sanitizing door handle and/or components of such sanitizing door handle. Some implementations of the invention are directed toward a manual sanitizing door handle while some implementations of the invention are directed toward an auto-sanitizing door handle. According to some implementations of the invention, a sanitizing fluid is dispensed directly onto an exterior surface of the sanitizing door handle in connection with an operation of the door handle to sanitize the door handle. According to some implementations of the invention, a sanitizing fluid is dispensed directly onto a user's hand(s) in connection with an operation of the door handle to sanitize the user's hand(s).

Abstract: An ergonomic scent diffuser having a first housing with electrical components connected to a second housing having a heating element disposed within. Slidably connected to the second housing is a cap. The cap has depressions adjacent an outer end to provide an ergonomic grip. The cap also has guide rails and retaining members that retain and position a fragrance emitting member over the heating element.

Abstract: A system for releasing flavor comprises: a plurality of compartments adapted to receive a respective plurality of capsules, each capsule containing therein a flavor material; a dispenser system configured for dispensing into an environment a fluid obtained from at least one flavor material; and a controller configured for automatically selecting a dispensing protocol, for signaling the dispenser system to dispense fluids obtained from at least one flavor material contained in at least one capsule of the compartments, and for automatically re-executing the selecting and the signaling, according to a shuffle protocol.

Abstract: A heating and atomizing aroma diffuser includes a cover with an outlet thereof, an atomization core including a heating member and a liquid conduction member surrounding around the heating member, a spice storage, an airflow generator with an inlet thereof and a control unit. The inlet, the airflow generator, the spice storage, the atomization core and the outlet are connected to cooperatively form an air passageway thereof. The control unit is electrically connected to the heating member and the airflow generator to drive the heating member to generate heat, so that spice liquid adsorbed on a surface of the liquid conduction member is atomized into steam by high temperature, and then simultaneously drive the steam to diffuse into the air through the air passageway, thereby the steam can be diffused rapidly and sufficiently into the air, and has widespread spectrum and strong fragrance.

Abstract: A sanitizing apparatus that includes a booth having a top portion, a front portion and a rear portion, with the rear portion having a set of inlets that face the front portion and the top portion having a first set of outlets such that the set of inlets and the first set of outlets are connected to each other; an air pump disposed in the rear portion configured to take in air so that the air downwardly comes out of the first set of outlets of the top portion; a filter disposed in the rear portion over the air pump wherein the filter filters the air coming out of the air pump; a ultraviolet (UV) light source disposed in the rear portion over the air pump; and a sanitizing solution spray unit installed on the front portion for spraying a sanitizing solution towards the rear portion to a user.

Abstract: A nonwoven web that contains a plurality of fibers formed from a polyolefin composition is provided. The polyolefin composition contains a rigid propylene polymer that has a relatively high melting temperature and modulus of elasticity, which can provide good strength and durability to the nonwoven web. The polyolefin composition also contains a ductile propylene polymer that has a relatively high melt flow index, which can help achieve relatively fine fibers that minimize the stiffness of the web. In addition to a rigid and ductile polymer, the polyolefin composition also contains a slip additive (e.g., fatty acid derivative). Among other things, such an additive can even further enhance the overall softness of the composition.

Abstract: The invention concerns a hygiene product comprising at least one layer of a nonwoven wherein the nonwoven layer comprises man-made cellulosic fibers wherein the layer or the layers has or have a rewet value of equal to or less than 30% and a liquid strike through time of equal to or less than 6 seconds for the use in disposable hygiene products, such as diapers, feminine pads and incontinence products or in wet wipes like toilet wipes, facial wipes, cosmetic wipes, baby wipes and sanitary wipes for cleaning and disinfection.

Abstract: One aspect of the invention provides a method of sequentially inducing macrophage conversion in a wound. The method includes: (a) administering IL-4 to induce conversion of a first population of wound macrophages in the wound to M2A macrophages; and then (b) administering IL-10, dexamethasone, or a dexamethasone analog to induce conversion of a second population of wound macrophages in the wound to M2C macrophages.

Abstract: A joint spacer is provided for treatment of a joint of a human subject, the joint spacer including a pouch having a wall including a dermal graft material. The joint spacer is configured to be inserted into a space of the joint, and is shaped, when the pouch is inserted into the space and filled, to provide mechanical support to the joint. Other embodiments are also described.

Abstract: The present invention discloses elastic macro porous scaffold and a process for the preparation thereof. The present invention also provides a process for the preparation of macroporous, elastic nano particulate scaffolds comprising of coated or grafted cross linkable nanoparticles, and a crosslinker prepared by crosslinking during ice templating, wherein the modulus increases linearly with temperature.

Abstract: Provided herein are biocompatible hydrogel polymers capable of gelling in vivo comprising a therapeutic agent such as a protein or other biomolecule and kits comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and at least one therapeutic agent. The biocompatible hydrogel polymer is bioabsorbable and releases the therapeutic agent at a target site, avoiding systemic exposure and achieving a controlled delivery.

Abstract: Combination cellulose materials and methods of making and using these materials. The combination material includes a first cellulosic material and a second cellulosic material.

Abstract: Exemplary embodiments of the present invention provide adhesion barriers having anti-adhesion and tissue fixating properties. The adhesion barriers are formed of fatty acid based films. The fatty acid-based films may be formed from fatty acid-derived biomaterials. The films may be coated with, or may include, tissue fixating materials to create the adhesion barrier. The adhesion barriers are well tolerated by the body, have anti-inflammation properties, fixate, well to tissue, and have a residence time sufficient to prevent post-surgical adhesions.

Abstract: The present invention discloses a compound heparin anticoagulant coating liquid, a microsphere for coating and its preparation methods and applications. In the present invention, the combination of curcumin and heparin can enhance the anticoagulation functions of heparin coating, and further enhance the stability using the properties of PLA-PEG-PLA drug-loaded sustained-release microspheres, achieving the functions of anti-tissue proliferation and anti-inflammatory reactions that cannot be achieved by coatings alone such as heparin or protein, which is very important for implanted devices such as artificial blood vessels, vascular stents and vascular patches to reduce thrombosis in the human body, lower postoperative complications and improve product lifespan.

Abstract: A medical/surgical lavage unit including internal ribs that extend into a void space of a suction tube attached to the lavage unit.

Abstract: A device for controlling blood flow occurring in a haemorrhagic zone of a biological tissue, includes a flexible plate arranged to be placed opposite this zone, the flexible plate including: substantially leaktight peripheral supporting elements, for applying on the tissue so that the zone is surrounded; a back wall delimiting, with the supporting elements, opposite the zone, a hollow space; connecting elements connecting the hollow space, externally to the flexible plate, to an external aspiration source for creating a vacuum in the hollow space for aspirating and tightly applying the surface of the tissue against the peripheral supporting elements; and a hollow stud placed between the zone and the back wall and hollowed out in its centre on the side of the zone along an axis substantially perpendicular to the back wall, and arranged to be in contact with the zone when the vacuum is created in the space.

Abstract: A medical fluid delivery system includes: a medical fluid delivery machine including a component having at least one of associated output data or associated test data; at least one of a (i) component output replacement limit and a component output soft limit for the component or (ii) a component testing replacement limit or a component testing soft limit for the component; and a computer programmed to store at least one of (i) or (ii), and for (i) analyze the output data to provide a first indication of how well the component is performing relative to the component output replacement limit and the component output soft limit, and for (ii) analyze the test data to provide a second indication of how well the at least one component is testing relative to the component testing replacement limit and the component testing soft limit.

Abstract: An extracorporeal blood treatment apparatus is provided comprising a filtration unit (2) connected to a blood circuit (17) and to a dialysis fluid circuit (32), a preparation device (9) for preparing and regulating the composition of the dialysis fluid; a control unit (12) is configured for determining or receiving a proposed value (Condprop) of a conductivity for the dialysis fluid in the dialysis supply line (8) and to determine a set value (Condset) for the conductivity in the dialysis fluid as a function of the proposed value (Condprop) and as a function of at least one of a second parameter (UF volume/W; WL/W) indicative of a patient fluid overload and a third parameter (gconc) chosen in the group including: a glucose concentration in the patient and a concentration-related parameter of at least glucose in the patient.

Abstract: The invention relates to a medical treatment device comprising a fluid system, which has a monitoring apparatus 27 for monitoring the treatment device, wherein the monitoring apparatus 27 is configured such that monitoring is based on the evaluation of the pressure in the fluid system of the medical treatment device. The invention further relates to a method for monitoring a medical treatment device, in which monitoring is based on the evaluation of the pressure in the fluid system. The treatment device is characterised by a compliance-determining apparatus 28 for determining the compliance in the fluid system, part of the fluid system or parts of the fluid system, wherein the compliance-determining apparatus 28 cooperates with the monitoring apparatus 27 in such a manner that the pressure-based monitoring takes place depending on the compliance of the fluid system.

Abstract: A fluid conduit includes a first portion having a first porosity, a second portion disposed immediately adjacent to the first portion, the second portion having a second porosity that is greater than the first porosity, and a third portion of the fluid conduit disposed immediately adjacent to the second portion, the third portion having a third porosity that is less than the second porosity. Each of the first portion, the second portion, and the third portion may be integrally formed as a single, continuous piece defining the fluid conduit.

Abstract: Provided is a filter apparatus, comprising two or more filter cartridges having a first end with an inlet and screen and a second end with an outlet and screen, and walls to contain a filter media held in a housing for holding the two or more filter cartridges in about the same orientation, and an attachment clamp connected to the housing. Also provided is a housing for holding two or more filter cartridges in about the same orientation and a method of using the filter apparatus and housing.

Abstract: Embodiments of the disclosure provide a system and method for detection of a transient air bubble in an arterial blood flow path during dialysis (e.g., hemodialysis). The system uses measurements from an optical sensor to remove one or more effects of common factors affecting the absorbance of the light incident on the arterial tubing. These factors include color of medium within the arterial tubing, tubing color, angle of illumination, and temperature of the optical detector. A variance of the measurements from the optical sensor are used to determine whether an air bubble is present.

Abstract: A chemical pump assembly useful for negative pressure therapy includes a chemical pump housing having an inner chamber, a reactor located within the inner chamber, an opening provided in the chemical pump housing, a first pull tab which extends from the inner chamber to ambient through the opening, and a removable layer connected to the first pull tab. The reactor is configured to react with a selected gas found in air so as to consume the selected gas when exposed to air in the inner chamber. The removable layer shields the reactor from air in the inner chamber atmosphere until the removable layer is removed.

Abstract: A system for anal and/or stomal irrigation comprises a reservoir (102) for an irrigating liquid, a catheter (100) comprising a catheter tip for insertion into the rectum and/or stoma of a user and for expelling of the irrigating liquid from the catheter tip, the catheter further comprising an expandable retention element (104), such as a balloon. A pump (101) is provided to pump the irrigating liquid from the reservoir to the catheter tip, and a user-operable control interface (123;125) comprising a dedicated emergency stop zone (125) is provided for receiving user input to withdraw the irrigating liquid from the retention element (100) for purging thereof in any operational state of the system.

Abstract: An irrigator system for delivering a volume of fluid from a fluid source to an abscess or wound. The irrigator system includes a fluid source connector for removably connecting to the fluid source, a fluid delivery nozzle for delivering the fluid to the abscess or wound, and a shield removably positioned around the fluid delivery nozzle to protect the fluid delivery nozzle.

Abstract: A system for injecting fluid to a patient is provided. The system provides manual or automatic verification and identification of the fluid to be injected, prior to, during or after injection. The system includes: a fluid having at least one active compound and at least one tracer compound; an injector configured to deliver the fluid to the patient through a fluid path set; at least one sensor coupled to at least one of the syringe, the injector, or the patient, configured to measure at least one property of the tracer in the fluid, and a feedback path to adjust at least one injection parameter of the injector based on at least one measurement from the at least one sensor.

Abstract: A method includes providing a medication delivery vehicle comprising a reservoir with a seal formed thereon and a cantilevered beam micro-machined from a layer of material and coupled to the reservoir, the cantilevered beam comprising a tip for puncturing the seal, applying an electric field to the cantilevered beam that impels the tip forward and causes the tip to break through the seal of the reservoir, and changing the electric field to impel the micro-machined tip backward and thereby release a medication from the reservoir. A computer program product and computer system corresponding to the method are also disclosed.

Abstract: A method and apparatus for a connection interface between a reservoir or syringe, infusion set tubing, and an infusion pump is provided. The reservoir, a base and a cap are connected to form an integrated unit that is capable of being inserted and secured in an infusion pump housing. The cap and the infusion pump are each provided with at least one sensor or at least one detectable feature, arranged to interact with at least one corresponding detectable feature or sensor on the other of the cap and infusion pump device, to detect one or more of the presence, position or other characteristic of the cap when the cap is aligned or coupled with the infusion pump housing. The detectable feature and sensor may be magnetic, RF, mechanical, optical or any combination.

Abstract: An infusion arrangement for administering a medical fluid includes a pump apparatus with an elastomeric membrane which forms a pump volume. The elastomeric membrane is elastically extended in a fill state, filled at least partially with medical fluid, of the pump volume and produces a delivery pressure on the pump volume. An infusion line is connected to the pump volume and provided with a patient access for fluid-conducting connection. A main fluid channel transfers medical fluid from the pump volume to the patient access. A monitoring device is connected to the infusion line and configured for monitoring the pump apparatus. The monitoring device has a differential pressure-measuring element connected to the main fluid channel and designed such that differential pressure formed along a channel portion of the main fluid channel can be detected by the differential pressure-measuring element and a delivery rate of the medical fluid can be indicated.